Company news

Paradigm Biopharmaceuticals Ltd. news in 2021

Paradigm Biopharmaceuticals Ltd.'s news releases, calls and decks from 2021, newest first.

View company

PAR reports postive topline results in heart failure model

December 16, 2021

Preliminary Results from Phase 2 MPS I Study

November 22, 2021

Paradigm CEO Paul Rennie to transition to Non-Exec Chairman

November 21, 2021

Paradigm cleared for phase 3 Trial by US FDA

November 2, 2021

Phase 2 Synovial Fluid Biomarker Study Update

October 25, 2021

Positive top-line results from preclinical study in ARDS

October 12, 2021

First MPS-VI patient dosed under Phase 2 trial in Brazil

September 30, 2021

Paradigm receives feedback from US FDA on ind submission

September 26, 2021

Aus ethics approval received for Phase 3 trial

September 23, 2021

2021 Annual Report and Appendix 4E

August 26, 2021

Paradigm reports IND application update

August 2, 2021

Paradigm submits responses to US FDA questions

June 29, 2021

Paradigm receives key regulatory approvals for MPS vi study

June 17, 2021

IND questions received from US FDA

May 24, 2021

Paradigm achieves first revenue

May 18, 2021

Paradigm provides IND application update

April 25, 2021

Paradigm doses first participant in Synovial Fluid Trial

April 13, 2021

Paradigm and Bene Execute New Collaboration Agreement

March 30, 2021

Paradigm delivers IND to US FDA for Pivotal OA Program

March 25, 2021

Consistent pain reduction and improvement in function data

February 2, 2021

Response to ASX Query

January 21, 2021

Decks in 2021